Form 4: Allogene Therapeutics CEO David Chang Sells Shares to Cover Tax Obligations

Allogene Therapeutics CEO David Chang sold 46,668 shares of common stock on March 14, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 14, 2025, David Chang, the President and CEO of Allogene Therapeutics, sold 46,668 shares of Allogene's common stock at a price of $1.96 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units, as mandated by the Issuer's equity incentive plan.
• Following the transaction, Chang directly owns 5,276,569 shares of Allogene's common stock.
• Chang also indirectly owns shares through several trusts: 856,044 shares via the RTC 2019 Trust, 856,044 shares via the JEC 2019 Trust, and 1,201,108 shares via the Chang 2006 Family Trust.
• Chang also acquired 6000 shares of the Issuer's common stock on March 14, 2025 pursuant to an employee stock purchase program.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency into the transactions of company executives and their potential impact on the stock's price and investor sentiment.

Stakeholder Impact

• Shareholders may be interested in insider trading activity as an indicator of management's confidence in the company.
• The sale of shares could exert downward pressure on the stock price, although the impact is likely to be minimal given the relatively small number of shares sold compared to the total outstanding shares.

Key Dates